Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELANE | P08246 | 20/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13299874 | 0.94 | ELANE (0.42) | ELANE | |
| SCHEMBL13299857 | 0.94 | ELANE (0.38) | ELANE | |
| SCHEMBL13299852 | 0.92 | ELANE (0.43) | ELANE | |
| SCHEMBL13814744 | 0.90 | ELANE (0.46) | ELANE | |
| SCHEMBL13299705 | 0.90 | ELANE (0.42) | ELANE | |
| SCHEMBL13299855 | 0.90 | ELANE (0.46) | ELANE | |
| SCHEMBL13299735 | 0.89 | ELANE (0.42) | ELANE | |
| SCHEMBL13814747 | 0.89 | ELANE (0.42) | ELANE | |
| SCHEMBL13299704 | 0.88 | ELANE (0.43) | ELANE | |
| SCHEMBL13814754 | 0.88 | ELANE (0.41) | ELANE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2010065461-A1 | TRI-PEPTIDE INHIBITORS OF SERINE ELASTASES | ACCUTHERA, INC. (US) | 2010-06-10 | — | — | WO | disclosed |
| US-20090156509-A1 | Tri-peptide Inhibitors of Serine Elastases | ACCUTHERA, INC. (US) | 2009-06-18 | — | — | US | disclosed |
| US-20090156509-A1 | Tri-peptide Inhibitors of Serine Elastases | ACCUTHERA, INC. (US) | 2009-06-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090156509-A1 | Tri-peptide Inhibitors of Serine Elastases | SCTR, CTRC, SERPINB1 | ELANE 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.